Integrating multiple outcomes of first-line immunotherapy-based regimens for advanced hepatocellular carcinoma: A network meta-analysis of phase III trials.

Crit Rev Oncol HematolJun 5, 2026 (epub)
Clinical ResearchOncology (Medical)

Guilin Nie, Xinming Li, Yaoqun Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis evaluated phase III trials of immunotherapy regimens for advanced hepatocellular carcinoma (HCC) involving 7908 patients. The study found that sintilimab plus IBI305 had the highest probability of improving overall survival (OS) with a SUCRA score of 0.91, while finotonlimab plus bevacizumab showed superior performance across multiple outcomes, including OS and progression-free survival (PFS).

Key findings

  • Sintilimab plus IBI305 had the highest SUCRA score for overall survival at 0.91.
  • Finotonlimab plus bevacizumab was most effective for overall survival in younger patients with a score of 0.95.
  • Finotonlimab plus bevacizumab and atezolizumab plus bevacizumab outperformed other regimens in integrated outcomes.
  • Finotonlimab plus bevacizumab showed a SUCRA score of 0.86 for progression-free survival in the overall population.

Why it matters

Understanding the comparative effectiveness of immunotherapy regimens for advanced HCC is crucial for optimizing treatment strategies. This analysis provides insights into which combinations may offer the best outcomes in terms of survival, safety, and quality of life.

Source

PubMed · PMID 42250662

Published in Crit Rev Oncol Hematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.